---
title: "\"Performance\" Pharmaron's annual net profit is 1.664 billion RMB, down 7.2%, with a final dividend of 20 cents"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281061356.md"
description: "Pharmaron announced its 2025 annual performance, with revenue of 14.095 billion RMB (same below), an increase of 14.8% year-on-year; gross profit of 4.857 billion RMB, an increase of 17.1%. It recorded a net profit of 1.664 billion RMB, a decline of 7.2%, with earnings per share of 0.9443 RMB. The final dividend remains at 0.20 RMB"
datetime: "2026-03-30T17:33:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281061356.md)
  - [en](https://longbridge.com/en/news/281061356.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281061356.md)
---

# "Performance" Pharmaron's annual net profit is 1.664 billion RMB, down 7.2%, with a final dividend of 20 cents

Pharmaron (03759.HK) announced its 2025 annual results, with revenue of RMB 14.095 billion, an increase of 14.8% year-on-year; gross profit of RMB 4.857 billion, an increase of 17.1%. It recorded a net profit of RMB 1.664 billion, a decline of 7.2%, with earnings per share of 94.43 cents. The final dividend remains at 20 cents

### Related Stocks

- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [300759.CN](https://longbridge.com/en/quote/300759.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [159570.CN](https://longbridge.com/en/quote/159570.CN.md)

## Related News & Research

- [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md)
- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds](https://longbridge.com/en/news/286487023.md)